#Uk moderna second dose timing skin#

#Uk moderna second dose timing skin#

Tuberculin skin testing (TST) and interferon gamma release assay (IGRA).Guidance on reporting adverse events following immunization (AEFI).Uncommon, rare and very rare adverse events.Concurrent administration with other vaccines.Overview of authorized XBB.1.5 vaccines by product and age oĝose and route of administration of available products.Suggested intervals between previous SARS-CoV-2 infection and COVID-19 vaccination Individuals previously infected with SARS-CoV-2.Pregnancy registry information by vaccine product Immunization schedule for a primary series, by COVID-19 vaccine Immunogenicity, efficacy and effectiveness.Preparations authorized for use in Canada.This information is captured in the table of updates. June 9, 2023: Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series.July 11, 2023: Guidance on the use of COVID-19 vaccines in the fall of 2023.September 12, 2023: Addendum to the guidance on the use of COVID-19 vaccines in the fall of 2023.This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI): Last partial content update: October 20, 2023 October 27, 2023: Updated guidance on the use of COVID-19 vaccines in individuals who have not previously been vaccinated against COVID-19 (PDF).This chapter has not yet been updated with the following statement from the National Advisory Committee on Immunization (NACI): Until this time, there will be differences in schedule guidance between vaccine product monographs and this COVID-19 vaccine chapter. In the coming weeks, NACI will provide additional guidance on the available COVID-19 vaccine formulations and products, optimal number of doses of COVID-19 vaccines and other considerations for individuals who have not been previously vaccinated (e.g., by age and for those who are immunocompromised).